Healthcare [ 5/11 ] | Drug Manufacturers—Specialty & Generic [ 32/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 10, 22 | -0.06 Increased by +75.00% | -0.04 Decreased by -2.04 K% |
| May 16, 22 | -0.07 Increased by +30.00% | -0.03 Decreased by -4.44 K% |
| Mar 31, 22 | -0.06 Increased by +53.85% | -0.04 Decreased by -1.25 K% |
| Nov 22, 21 | -0.12 Increased by +20.00% | -0.06 Decreased by -1.67 K% |
| Apr 15, 21 | -0.24 Decreased by -200.00% | -0.06 Decreased by -5.00 K% |
| Nov 9, 20 | -0.10 Increased by +16.67% | -0.05 Decreased by -2.00 K% |
| Aug 17, 20 | -0.13 Increased by +18.75% | -0.08 Decreased by -781.25% |
| May 18, 20 | -0.15 Increased by +21.05% | -0.06 Decreased by -2.50 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 1.45 M Increased by +25.85% | 71.70 K Increased by +100.69% | Increased by +4.93% Increased by +100.55% |
| Dec 31, 22 | 2.15 M Decreased by -99.90% | -3.40 M Increased by +56.44% | Decreased by -158.23% Decreased by -44.45 K% |
| Sep 30, 22 | 1.51 M Increased by +98.13% | -4.40 M Increased by +64.41% | Decreased by -292.15% Increased by +82.04% |
| Jun 30, 22 | 39.85 K Decreased by -99.01% | -8.40 M Increased by +9.84% | Decreased by -21.07 K% Decreased by -8.98 K% |
| Mar 31, 22 | 1.15 M Decreased by -71.90% | -10.35 M Increased by +32.67% | Decreased by -896.88% Decreased by -139.60% |
| Dec 31, 21 | 2.20 B Increased by +60.38 K% | -7.81 M Increased by +61.65% | Decreased by -0.36% Increased by +99.94% |
| Sep 30, 21 | 759.96 K Decreased by -82.33% | -12.36 M Decreased by -65.14% | Decreased by -1.63 K% Decreased by -834.50% |
| Jun 30, 21 | 4.01 M Increased by +2.16% | -9.31 M Increased by +17.30% | Decreased by -232.19% Increased by +19.06% |
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.